Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome

Overt renal disease in primary Sjögren's syndrome (pSS) manifests as interstitial nephritis and glomerulonephritis. This single centre study aims to describe the natural history and treatment outcome of renal disease in pSS. pSS patients with renal disease were identified, and clinical features...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2019-05, Vol.37 Suppl 118 (3), p.123-132
Hauptverfasser: Goules, Andreas, Geetha, Duvuru, Arend, Lois J, Baer, Alan N
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 132
container_issue 3
container_start_page 123
container_title Clinical and experimental rheumatology
container_volume 37 Suppl 118
creator Goules, Andreas
Geetha, Duvuru
Arend, Lois J
Baer, Alan N
description Overt renal disease in primary Sjögren's syndrome (pSS) manifests as interstitial nephritis and glomerulonephritis. This single centre study aims to describe the natural history and treatment outcome of renal disease in pSS. pSS patients with renal disease were identified, and clinical features, renal biopsy findings, treatment details and renal outcome were recorded. Of the 20 pSS patients with renal disease, 14 had interstitial nephritis (IN), 3 had glomerulonephritis (GN) and 3 had both entities. In the IN group, 3 patients presented with chronic kidney disease (CKD), 4 with renal tubular acidosis (RTA), 2 with symptomatic hypokalaemia, 4 with renal colic and 1 with haematuria/proteinuria. Eight of 14 patients with IN received systemic immunosuppression (IS) during renal disease course and in 6 patients no beneficial effect was observed on renal function, hypokalaemia and RTA. Six of 14 IN patients developed CKD while 5 of them preserved normal renal function during follow-up. In the GN group, 2 patients presented with CKD, 3 with proteinuria/haematuria and 1 with nephrotic proteinuria. GN renal biopsy findings revealed membranoproliferative (MPGN) (n=3), focal segmental glomerulosclerosis (n=1) and fibrillary glomerulopathy (n=1). All 3 MPGN patients had cryoglobulinaemia and in 1 patient cryoglobulinaemic MPGN was clinically diagnosed. All GN patients were treated with immunosuppressive therapy, with stabilisation or improvement of renal function in the 4 cryoglobulinaemia-associated GN patients only. Interstitial nephritis follows a slow course and does not improve with systemic immunosuppression while GN has a favourable treatment response in those with MPGN pathology.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2282445536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2282445536</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-3d31bc159c4a074067326807b883d180c6e9191eade7c97900a0fab20b5beb093</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRb0A0VL4BeQdbCL5FT_YoYqXVAmJh2AX2fEUUiVOsZ1K_TF-gB8jgrCaWZxzNXMP0JxwwwpdyrcZOk5pQwiTpVRHaMapkEIqPkevjxBsi5uw69sddBDyuONtbDob9_hp8_31HiGcJ5z2wce-g0scbB7i6Hw0KfcjZIPHOYLNv3Y_5HrETtDh2rYJTqe5QC8318_Lu2L1cHu_vFoVW0ZpLrjn1NW0NLWwRAky3sSkJsppzT3VpJZgqKFgPajaKEOIJWvrGHGlA0cMX6CLv9xt7D8HSLnqmlRD29oA_ZAqxjQToiy5HNGzCR1cB76anqz-y-A_kyNbqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2282445536</pqid></control><display><type>article</type><title>Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome</title><source>Alma/SFX Local Collection</source><creator>Goules, Andreas ; Geetha, Duvuru ; Arend, Lois J ; Baer, Alan N</creator><creatorcontrib>Goules, Andreas ; Geetha, Duvuru ; Arend, Lois J ; Baer, Alan N</creatorcontrib><description>Overt renal disease in primary Sjögren's syndrome (pSS) manifests as interstitial nephritis and glomerulonephritis. This single centre study aims to describe the natural history and treatment outcome of renal disease in pSS. pSS patients with renal disease were identified, and clinical features, renal biopsy findings, treatment details and renal outcome were recorded. Of the 20 pSS patients with renal disease, 14 had interstitial nephritis (IN), 3 had glomerulonephritis (GN) and 3 had both entities. In the IN group, 3 patients presented with chronic kidney disease (CKD), 4 with renal tubular acidosis (RTA), 2 with symptomatic hypokalaemia, 4 with renal colic and 1 with haematuria/proteinuria. Eight of 14 patients with IN received systemic immunosuppression (IS) during renal disease course and in 6 patients no beneficial effect was observed on renal function, hypokalaemia and RTA. Six of 14 IN patients developed CKD while 5 of them preserved normal renal function during follow-up. In the GN group, 2 patients presented with CKD, 3 with proteinuria/haematuria and 1 with nephrotic proteinuria. GN renal biopsy findings revealed membranoproliferative (MPGN) (n=3), focal segmental glomerulosclerosis (n=1) and fibrillary glomerulopathy (n=1). All 3 MPGN patients had cryoglobulinaemia and in 1 patient cryoglobulinaemic MPGN was clinically diagnosed. All GN patients were treated with immunosuppressive therapy, with stabilisation or improvement of renal function in the 4 cryoglobulinaemia-associated GN patients only. Interstitial nephritis follows a slow course and does not improve with systemic immunosuppression while GN has a favourable treatment response in those with MPGN pathology.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 31464673</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and experimental rheumatology, 2019-05, Vol.37 Suppl 118 (3), p.123-132</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31464673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goules, Andreas</creatorcontrib><creatorcontrib>Geetha, Duvuru</creatorcontrib><creatorcontrib>Arend, Lois J</creatorcontrib><creatorcontrib>Baer, Alan N</creatorcontrib><title>Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>Overt renal disease in primary Sjögren's syndrome (pSS) manifests as interstitial nephritis and glomerulonephritis. This single centre study aims to describe the natural history and treatment outcome of renal disease in pSS. pSS patients with renal disease were identified, and clinical features, renal biopsy findings, treatment details and renal outcome were recorded. Of the 20 pSS patients with renal disease, 14 had interstitial nephritis (IN), 3 had glomerulonephritis (GN) and 3 had both entities. In the IN group, 3 patients presented with chronic kidney disease (CKD), 4 with renal tubular acidosis (RTA), 2 with symptomatic hypokalaemia, 4 with renal colic and 1 with haematuria/proteinuria. Eight of 14 patients with IN received systemic immunosuppression (IS) during renal disease course and in 6 patients no beneficial effect was observed on renal function, hypokalaemia and RTA. Six of 14 IN patients developed CKD while 5 of them preserved normal renal function during follow-up. In the GN group, 2 patients presented with CKD, 3 with proteinuria/haematuria and 1 with nephrotic proteinuria. GN renal biopsy findings revealed membranoproliferative (MPGN) (n=3), focal segmental glomerulosclerosis (n=1) and fibrillary glomerulopathy (n=1). All 3 MPGN patients had cryoglobulinaemia and in 1 patient cryoglobulinaemic MPGN was clinically diagnosed. All GN patients were treated with immunosuppressive therapy, with stabilisation or improvement of renal function in the 4 cryoglobulinaemia-associated GN patients only. Interstitial nephritis follows a slow course and does not improve with systemic immunosuppression while GN has a favourable treatment response in those with MPGN pathology.</description><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo1kMtOwzAQRb0A0VL4BeQdbCL5FT_YoYqXVAmJh2AX2fEUUiVOsZ1K_TF-gB8jgrCaWZxzNXMP0JxwwwpdyrcZOk5pQwiTpVRHaMapkEIqPkevjxBsi5uw69sddBDyuONtbDob9_hp8_31HiGcJ5z2wce-g0scbB7i6Hw0KfcjZIPHOYLNv3Y_5HrETtDh2rYJTqe5QC8318_Lu2L1cHu_vFoVW0ZpLrjn1NW0NLWwRAky3sSkJsppzT3VpJZgqKFgPajaKEOIJWvrGHGlA0cMX6CLv9xt7D8HSLnqmlRD29oA_ZAqxjQToiy5HNGzCR1cB76anqz-y-A_kyNbqw</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Goules, Andreas</creator><creator>Geetha, Duvuru</creator><creator>Arend, Lois J</creator><creator>Baer, Alan N</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201905</creationdate><title>Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome</title><author>Goules, Andreas ; Geetha, Duvuru ; Arend, Lois J ; Baer, Alan N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-3d31bc159c4a074067326807b883d180c6e9191eade7c97900a0fab20b5beb093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goules, Andreas</creatorcontrib><creatorcontrib>Geetha, Duvuru</creatorcontrib><creatorcontrib>Arend, Lois J</creatorcontrib><creatorcontrib>Baer, Alan N</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goules, Andreas</au><au>Geetha, Duvuru</au><au>Arend, Lois J</au><au>Baer, Alan N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2019-05</date><risdate>2019</risdate><volume>37 Suppl 118</volume><issue>3</issue><spage>123</spage><epage>132</epage><pages>123-132</pages><issn>0392-856X</issn><abstract>Overt renal disease in primary Sjögren's syndrome (pSS) manifests as interstitial nephritis and glomerulonephritis. This single centre study aims to describe the natural history and treatment outcome of renal disease in pSS. pSS patients with renal disease were identified, and clinical features, renal biopsy findings, treatment details and renal outcome were recorded. Of the 20 pSS patients with renal disease, 14 had interstitial nephritis (IN), 3 had glomerulonephritis (GN) and 3 had both entities. In the IN group, 3 patients presented with chronic kidney disease (CKD), 4 with renal tubular acidosis (RTA), 2 with symptomatic hypokalaemia, 4 with renal colic and 1 with haematuria/proteinuria. Eight of 14 patients with IN received systemic immunosuppression (IS) during renal disease course and in 6 patients no beneficial effect was observed on renal function, hypokalaemia and RTA. Six of 14 IN patients developed CKD while 5 of them preserved normal renal function during follow-up. In the GN group, 2 patients presented with CKD, 3 with proteinuria/haematuria and 1 with nephrotic proteinuria. GN renal biopsy findings revealed membranoproliferative (MPGN) (n=3), focal segmental glomerulosclerosis (n=1) and fibrillary glomerulopathy (n=1). All 3 MPGN patients had cryoglobulinaemia and in 1 patient cryoglobulinaemic MPGN was clinically diagnosed. All GN patients were treated with immunosuppressive therapy, with stabilisation or improvement of renal function in the 4 cryoglobulinaemia-associated GN patients only. Interstitial nephritis follows a slow course and does not improve with systemic immunosuppression while GN has a favourable treatment response in those with MPGN pathology.</abstract><cop>Italy</cop><pmid>31464673</pmid><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2019-05, Vol.37 Suppl 118 (3), p.123-132
issn 0392-856X
language eng
recordid cdi_proquest_miscellaneous_2282445536
source Alma/SFX Local Collection
title Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T09%3A12%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renal%20involvement%20in%20primary%20Sj%C3%B6gren's%20syndrome:%20natural%20history%20and%20treatment%20outcome&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Goules,%20Andreas&rft.date=2019-05&rft.volume=37%20Suppl%20118&rft.issue=3&rft.spage=123&rft.epage=132&rft.pages=123-132&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2282445536%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2282445536&rft_id=info:pmid/31464673&rfr_iscdi=true